Results 41 to 50 of about 3,015 (158)
Macrocyclic Inhibitors Targeting the Prime Site of the Fibrinolytic Serine Protease Plasmin
ChemMedChem, Volume 19, Issue 23, December 2, 2024.New macrocyclic inhibitors addressing the S1 pocket and the prime site of the fibrinolytic serine protease plasmin have been developed. A strong potency was found for compounds containing a substituted biphenylalanine as P1’ residue, some of them already exhibit a certain selectivity as plasmin inhibitors.
Simon J. A. Wiedemeyer +5 more
wiley +1 more source
Журнал инфектологии, 2016 The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and ...
A. V. Rudakova +4 more
doaj
Case Reports in Gastroenterology, 2015 Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda +11 more
doaj +1 more source
An Updated Structure of Oxybutynin Hydrochloride
Advanced Science, Volume 11, Issue 40, October 28, 2024.Oxybutynin (Ditropan) is a widely prescribed muscarinic antagonist for treating the overactive bladder. Previous powder X‐ray diffraction (PXRD) structures has problems like inconsistency with 2D chemical structure and X‐ray‐induced photoreduction. Here microcrystal electron diffraction (MicroED) is used to unveil a definitive and improved 3D structure
Jieye Lin +3 more
wiley +1 more source
Терапевтический архив, 2014 Triple therapy with pegylated interferon-α, ribavirin, and simeprevir is now optimal among the antiviral treatment options available in the Russian Federation for patients with chronic hepatitis C (CHC), including in the compensated stage of liver ...
É Z Burnevich
doaj
PLoS ONE, 2017 IntroductionHepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality.
Delphine Degré +17 more
doaj +1 more source
Clinical and Translational Science, Volume 17, Issue 10, October 2024.Abstract Next‐generation sequencing (NGS) has transformed pharmacogenomics (PGx), enabling thorough profiling of pharmacogenes using computational methods and advancing personalized medicine. The Thai Pharmacogenomic Database‐2 (TPGxD‐2) analyzed 948 whole genome sequences, primarily from the Electricity Generating Authority of Thailand (EGAT) cohort ...
Shobana John +13 more
wiley +1 more source
Журнал инфектологии, 2016 In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and ...
D. A. Gusev +4 more
doaj
European Journal of Immunology, Volume 54, Issue 8, August 2024.In patients with hepatitis C cirrhosis who are treated with 2G DAA, predicted weak NK‐cell‐mediated immunity may predispose to HCC development more than predicted intermediate or strong NK‐cell‐mediated immunity. Background and aims Second‐generation direct‐acting antivirals (2G DAA) to cure HCV have led to dramatic clinical improvements.
James C. Ryan +6 more
wiley +1 more source
Case Reports in Hematology, 2016 Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin
Nikolaos Papadopoulos +4 more
doaj +1 more source